Diamyd Medical AB (FRA:DMN) COGS-to-Revenue : 12.00 (As of Feb. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB COGS-to-Revenue?

Diamyd Medical AB's Cost of Goods Sold for the three months ended in Feb. 2025 was €0.10 Mil. Its Revenue for the three months ended in Feb. 2025 was €0.01 Mil.

Diamyd Medical AB's COGS to Revenue for the three months ended in Feb. 2025 was 12.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Diamyd Medical AB's Gross Margin % for the three months ended in Feb. 2025 was -1,100.00%.

Diamyd Medical AB COGS-to-Revenue Historical Data

The historical data trend for Diamyd Medical AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB COGS-to-Revenue Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

COGS-to-Revenue

Get a 7-Day Free Trial

13.18

9.80

9.74

6.67

29.45

Diamyd Medical AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
COGS-to-Revenue	Get a 7-Day Free Trial															35.00	20.25	36.50	47.00	12.00

Diamyd Medical AB COGS-to-Revenue Calculation

Diamyd Medical AB's COGS to Revenue for the fiscal year that ended in Aug. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.324	/	0.011
	=	29.45

Diamyd Medical AB's COGS to Revenue for the quarter that ended in Feb. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.096	/	0.008
	=	12.00

Diamyd Medical AB (FRA:DMN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Diamyd Medical AB's Gross Margin % for the three months ended in Feb. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.096 / 0.008
	=	-1,100.00 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Diamyd Medical AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

DYMDF:USA DMYD B:Sweden

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines